Drug reference
linagliptin-metformin
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Endocrine (Peptide analogues)
Mechanism of action
Linagliptin: Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity from glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are inactivated by the DPP-4 enzyme; Metformin: Decreases hepatic glucose production; decreases GI intestinal glucose absorption.
Common side effects
- Nasopharyngitis
- Hypoglycemia
- Acute pancreatitis
- Diarrhea
Related conditions
Frequently asked questions
What drug class is linagliptin-metformin?
linagliptin-metformin belongs to: Endocrine.
How does linagliptin-metformin work?
Linagliptin: Dipeptidyl peptidase 4 (DPP-4) inhibitor; increases and prolongs incretin hormone activity from glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are inactivated by the DPP-4 enzyme; Metformin: Decreases hepatic glucose production; decreases GI intestinal glucose absorption.
What are the common side effects of linagliptin-metformin?
Nasopharyngitis, Hypoglycemia, Acute pancreatitis, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.